相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
66.7%
终止
2
33.3%
暂无批准数据
- Azenta, Inc. has appointed Board member Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta as executive officer and director. - The Board has retained Heidrick & Struggles to lead a search for a permanent CEO while reaffirming fourth quarter fiscal 2026 total revenue guidance. - Fourth quarter fiscal 2026 adjusted EBITDA will be impacted by a one-time consulting expense of approximately $3 million, excluding which the Company would reaffirm adjusted EBITDA. - Dr. Madaus brings more than 30 years of diagnostics and life science tools leadership experience, including prior CEO roles at Millipore, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.
- The global bioprocessing equipment market was valued at $48.1 billion in 2025 and is projected to reach $152.2 billion by 2035, expanding at a CAGR of 12.3%, according to Global Market Insights Inc. - Rising demand for biologics and biosimilars, rapid expansion of cell and gene therapy manufacturing, and growing adoption of single-use bioprocessing systems are key growth drivers. - North America held the largest market share at 38% in 2025, while Asia Pacific is projected to be the fastest-growing region with a CAGR of approximately 13.7%. - Danaher led the competitive landscape with over 29% market share in 2025, with the top five players collectively holding approximately 70% of the market.
- Repligen Corp announced a cash-and-stock acquisition of BioLife Solutions valued at approximately $1.5 billion to strengthen its position in the cell therapy manufacturing sector. - BioLife's biopreservation and cell-processing technologies are used in roughly 90% of commercially approved cell therapies, offering Repligen a high-margin recurring revenue stream. - The deal values BioLife at $31 per share, a 6.2% premium, and is expected to close in the fourth quarter of 2026 pending regulatory and shareholder approvals. - Repligen projects the cell therapy market will grow from under $7 billion to approximately $19 billion by decade's end, with over 1,100 cell therapies in the global pipeline.
- The global preparative and process chromatography market is projected to grow from $13.74 billion in 2025 to $29.53 billion by 2035, at a CAGR of 8.20%. - North America held the largest market share at approximately 34.55% in 2025, with the U.S. market alone expected to reach $7.28 billion by 2035. - The biopharmaceutical industry remains the dominant end-user segment, accounting for 43.56% of revenue, driven by monoclonal antibody and recombinant protein production. - Continuous chromatography, single-use technologies, and AI-enabled process optimization are emerging as key trends accelerating market adoption globally.
- Clark et al. demonstrated that a dsRNA-specific affinity resin reduces dsRNA impurities by over 100-fold, reaching levels as low as ~0.00007% w/w while preserving mRNA integrity. - Optimized IVT protocols combined with affinity purification eliminated immunogenicity entirely, with interferon levels indistinguishable from negative controls in A549-cell assays. - Vazyme's EasyAna dsRNA ELISA Kit enabled precise trace-level quantification with a detection limit below 10 pg/mL, distinguishing protocol differences that traditional dot blots would miss. - The study establishes a complete upstream-downstream solution pairing enzyme engineering to suppress dsRNA formation with affinity chromatography and sensitive ELISA detection for regulatory-ready mRNA manufacturing.
- Yokogawa Corporation of America and Repligen have announced a collaboration to integrate OpreX Bio Pilot with MAVERICK® for enhanced automated control of glucose and lactate levels in cell cultures. - The partnership enables continuous, real-time analysis of critical bioprocess parameters without manual sampling or complicated calibration models, supporting improved data management. - The integration aims to minimize batch failures, improve productivity, and reduce time to market for biopharmaceutical product development. - Initial scientific data from this collaboration will be presented at BioProcess International on September 17th, 2025, with demonstrations currently underway at facilities in Tokyo and Waltham.
